ArticleHuman vaccines & immunotherapeutics2026

Safety of nirsevimab in children aged 0-24 months: Analysis based on EudraVigilance data (2023-2025).

Cristina Morciano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.